Cardiovascular disease remains the leading cause of morbidity and mortality in the United States, despite major improvements in atherosclerotic cardiovascular disease (ASCVD) risk management and prevention. Most Americans who had an ASCVD event reported at least one risk factor beforehand. So how do we move patients toward ideal cardiovascular health?
Join the experts in this session discussing significant changes in the recent 2019 American College of Cardiology/American Heart Association (ACC/AHA) recommendations, including those for exercise, low-dose aspirin use, physical activities, tobacco use, and team-based care.
At the completion of this application-based activity, participants will be able to:
- Discuss recent 2019 evidence-based updates from ACC/AHA on primary prevention of ASCVD.
- Identify the risk factors that increase ASCVD risk.
- Discuss the reasoning for the recent low-dose aspirin recommendation in the ACC/AHA guidelines.
- Describe recommendations for appropriately selecting glycemic-lowering medications to reduce ASCVD risk in patients with type 2 diabetes.
- Formulate patient-centered treatment plans for primary prevention patients with and without diabetes to reduce ASCVD.
Activity type: Application-based
Target Audience: Pharmacists
Learning Level: 2
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The following archived webinar is approved for 1.5 contact hour of CPE credit (0.15 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-20-079-H01-P.
To obtain credit for completing Stopping a Killer: 2020 Update on Reducing ASCVD Risk, participants will need to watch the archived webinar, complete the assessment with a grade of 70% or better, complete the evaluation questions, and then CLAIM credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.
APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education assessment. Please note that you will not be permitted to submit the assessment a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.Initial release date: April 1, 2020
Expiration date: March 22, 2023 - No credit granted after this date
Stopping a Killer: 2020 Update on Reducing ASCVD Risk is an activity for pharmacists developed by the American Pharmacists Association. © 2020 American Pharmacists Association
Joseph Saseen, PharmD and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria.
Susan Cornell, PharmD, declares that shie is a consultant for Novo Nordisk and a member of the Lifescan and Novo Nordisk speaker bureaus.For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures.
Conflicts of interest have been resolved through content review by Helen Sairany, BA, PharmD, MBA, BCACP, Director of Content Development & Partnership at the American Pharmacists Association.
This learning product is a component of the APhA2020 Virtual Education package and is part of the Trending Topics in Ambulatory Care series.
Computer and internet access are required to complete this activity. Please visit our website to view the Technology System Requirements in order to have a positive learning experience.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-20-079-H01-P||0.15 CEUs||March 22, 2020 - March 22, 2023|